Key result
Postlicensure surveillance of new rotavirus vaccines is essential to monitor for rare adverse events such as intussusception, despite demonstrated safety in clinical trials of >60,000 infants.
Why the study?
What are the postlicensure safety issues, particularly intussusception, associated with rotavirus vaccines in infants?
What are the postlicensure safety issues, particularly intussusception, associated with rotavirus vaccines in infants?
This review highlights the need for standardized postmarketing surveillance to monitor rare adverse events like intussusception following rotavirus vaccine introduction.
No takes yet. Share an insight, caveat, or question.
Vigilance for intussusception after rotavirus vaccination remains warranted; leaves open optimal postlicensure monitoring strategies.
Bines et al. (2009) conducted a review in Rotavirus infection / vaccine safety. Rotavirus vaccines (Rotarix and RotaTeq) was evaluated. Postlicensure surveillance of new rotavirus vaccines is essential to monitor for rare adverse events such as intussusception, despite demonstrated safety in clinical trials of >60,000 infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: